Watchlist Price Alert

Kura Oncology Inc. (KURA)

NASDAQ: KURA · Real-Time Price · USD

5.68

-0.14 (-2.41%)

At close: May 30, 2025, 3:59 PM

5.85

2.99%

After-hours: May 30, 2025, 05:45 PM EDT

-2.41% (1D)

Bid	5.5
Market Cap	491.74M
Revenue (ttm)	67.99M
Net Income (ttm)	-181.89M
EPS (ttm)	-2.09
PE Ratio (ttm)	-2.72
Forward PE	-3.04
Analyst	Buy

Ask	5.9
Volume	504,550
Avg. Volume (20D)	1,307,079
Open	5.73
Previous Close	5.82
Day's Range	5.53 - 5.74
52-Week Range	5.41 - 23.48
Beta	0.50

About KURA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KURA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

-2.54%

Kura Oncology shares are trading lower. The compan... Unlock content with Pro Subscription

3 months ago

+1.8%

Kura Oncology shares are trading lower. The company announced topline results from KOMET-001.

News

1 month ago · seekingalpha.com

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Troy Wilson – President and Chief Executive Officer Mollie Leoni – Chief Medical Officer...

1 month ago · zacks.com

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.59 per share a year ago.

2 months ago · seekingalpha.com

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations throu...